Consumers in environments with high oversight may not value the extra protections if they expect identical products
The FDA and Eli Lilly have argued that adding commonly available vitamins does not create a clinically meaningful modification
Additionally, research to examine the newer and more potent weight-loss GLP-1 receptor agonists, semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly), would be particularly important.
the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period
Women who may become pregnant should use appropriate precautions